UC San Diego researchers have found a stem cell enzyme copy edits more than 20 tumor types, providing new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.
UC San Diego Health is the first hospital system in San Diego County to employ high-intensity, focused ultrasound (HIFU) for minimally invasive prostate cancer treatment.
UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.
The Adult Congenital Heart Disease program at UC San Diego Health has received accreditation from the Adult Congenital Heart Association (ACHA) as a comprehensive care center, a first for San Diego.
The multiple sclerosis drug teriflunomide, paired with targeted cancer therapy, markedly shrinks patient-derived glioblastomas grown in mice by reaching stem cells at the tumor’s root, according to a new UC San Diego School of Medicine study published in Science Translational Medicine.
Researchers with UC San Diego School of Medicine and Moores Cancer Center say active surveillance is safe for African American men with low-risk prostate cancer.
UC San Diego School of Medicine researchers will receive $6.4 million in National Institutes of Health grant funding to study how external signals and genetic variations influence the behavior of one cell type in particular: insulin-producing beta cells in the pancreas.
Researchers at Ludwig Institute for Cancer Research and University of California San Diego School of Medicine report that inhibiting a key enzyme caused human cancer cells associated with two major types of breast and ovarian cancer to die and in mouse studies reduced tumor growth.
